APOSTOLIA MARIA TSIMBERIDOU

TitleProfessor
InstitutionMD Anderson
DepartmentInvestigational Cancer Therapeutics
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2021 Sep 25. PMID: 34562230.
      Citations:    Fields:    
    2. Dev R, Zhong LL, Zarifa A, Albittar AA, Rubin L, Liu S, Yap TA, Dalal S, Hui D, Karp DD, Tsimberidou AM, Piha-Paul SA, Ahnert JR, Fu S, Meric-Bernstam F, Naing A. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs. 2021 Sep 24. PMID: 34559346.
      Citations:    Fields:    
    3. Dumbrava EI, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open. 2021 Aug 31; 6(5):100230. PMID: 34479035.
      Citations:    
    4. Tsimberidou AM, Shaw JV, Juric D, Verschraegen C, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis J, Mita M, Park H, Ellers-Lenz B, Tian H, Xiong W, Kaleta R, Kurzrock R. Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. J Hematol Oncol. 2021 08 18; 14(1):127. PMID: 34407844.
      Citations:    Fields:    
    5. Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. Adv Ther. 2021 08; 38(8):4581-4591. PMID: 34241781.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    6. Tsimberidou AM, Van Morris K, Vo HH, Eck S, Lin YF, Rivas JM, Andersson BS. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J Hematol Oncol. 2021 06 30; 14(1):102. PMID: 34193217.
      Citations: 3     Fields:    
    7. Tsimberidou AM, Beer PA, Cartwright CA, Haymaker C, Vo HH, Kiany S, Cecil ARL, Dow J, Haque K, Silva FA, Coe L, Berryman H, Bone EA, Nogueras-Gonzalez GM, Vining D, McElwaine-Johnn H, Wistuba II. Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. Clin Cancer Res. 2021 Jul 01; 27(13):3584-3594. PMID: 33947698.
      Citations: 1     Fields:    
    8. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs. 2021 10; 39(5):1357-1365. PMID: 33909232.
      Citations:    Fields:    
    9. Lazar V, Magidi S, Girard N, Savignoni A, Martini JF, Massimini G, Bresson C, Berger R, Onn A, Raynaud J, Wunder F, Berindan-Neagoe I, Sekacheva M, Braña I, Tabernero J, Felip E, Porgador A, Kleinman C, Batist G, Solomon B, Tsimberidou AM, Soria JC, Rubin E, Kurzrock R, Schilsky RL. Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. NPJ Precis Oncol. 2021 Apr 28; 5(1):33. PMID: 33911192.
      Citations:    
    10. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist. 2021 07; 26(7):588-596. PMID: 33783054.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    11. Al-Zubidi N, Gombos DS, Hong DS, Subbiah V, Fu S, Ahnert JR, Piha-Paul SA, Tsimberidou AM, Karp DD, Bernstam FM, Naing A. Overview of Ocular Side Effects of Selinexor. Oncologist. 2021 07; 26(7):619-623. PMID: 33728727.
      Citations:    Fields:    Translation:Humans
    12. Fountzilas E, Kurzrock R, Hiep Vo H, Tsimberidou AM. Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. J Natl Cancer Inst. 2021 Apr 06. PMID: 33823006.
      Citations:    Fields:    
    13. Naqvi MF, Vo HH, Vining D, Tsimberidou AM. Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series. Ther Adv Med Oncol. 2021; 13:17588359211001538. PMID: 33995588.
      Citations:    
    14. Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol. 2021 Mar 19; 5(1):21. PMID: 33742104.
      Citations: 1     
    15. Yao S, Janku F, Subbiah V, Stewart J, Patel SP, Kaseb A, Westin SN, Naing A, Tsimberidou AM, Hong D, Piha-Paul SA, Shi N, Johnston A, Bomalaski J, Fu S. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer. 2021 04; 124(9):1533-1539. PMID: 33674736.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    16. Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul S, Yilmaz B, Gong J, Naqvi MF, Tu SM, Campbell M, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist. 2021 07; 26(7):558-e1098. PMID: 33491277.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    17. Janku F, Sakamuri D, Kato S, Huang HJ, Call SG, Naing A, Holley VR, Patel SP, Amaria RN, Falchook GS, Piha-Paul SA, Zinner RG, Tsimberidou AM, Hong DS, Meric-Bernstam F. Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer. 2021 02 01; 127(3):391-402. PMID: 33119140.
      Citations: 1     Fields:    Translation:Humans
    18. Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang HJ, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F. Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. Clin Cancer Res. 2021 03 01; 27(5):1247-1255. PMID: 33115815.
      Citations:    Fields:    
    19. Tsimberidou AM, Müller P, Ji Y. Innovative trial design in precision oncology. Semin Cancer Biol. 2020 Oct 03. PMID: 33022355.
      Citations:    Fields:    
    20. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer. 2020 10; 8(2). PMID: 33097611.
      Citations: 3     Fields:    Translation:Humans
    21. Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA, Rodon Anhert J, Fu S, Naing A. Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel). 2020 Aug 16; 12(8). PMID: 32824391.
      Citations: 5     
    22. Tsimberidou AM, Elkin S, Dumanois R, Pritchard D. Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer. Clin Lung Cancer. 2020 11; 21(6):477-481. PMID: 32718774.
      Citations:    Fields:    Translation:Humans
    23. Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol. 2020; 9:7. PMID: 32337094.
      Citations: 2     
    24. Mahalingam D, Patel MR, Sachdev JC, Hart LL, Halama N, Ramanathan RK, Sarantopoulos J, Völkel D, Youssef A, de Jong FA, Tsimberidou AM. Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. Br J Clin Pharmacol. 2020 09; 86(9):1836-1848. PMID: 32207164.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    25. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev. 2020 Jun; 86:102019. PMID: 32251926.
      Citations: 19     Fields:    Translation:Humans
    26. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1). PMID: 32188704.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    27. Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu S. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080. PMID: 32080210.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    28. Said R, Guibert N, Oxnard GR, Tsimberidou AM. Circulating tumor DNA analysis in the era of precision oncology. Oncotarget. 2020 Jan 14; 11(2):188-211. PMID: 32010431.
      Citations: 15     Fields:    
    29. Fountzilas E, Kotoula V, Koliou GA, Giannoulatou E, Gogas H, Papadimitriou C, Tikas I, Zhang J, Papadopoulou K, Zagouri F, Christodoulou C, Koutras A, Makatsoris T, Chrisafi S, Linardou H, Varthalitis I, Papatsibas G, Razis E, Papakostas P, Samantas E, Aravantinos G, Bafaloukos D, Kosmidis P, Koumarianou A, Psyrri A, Pentheroudakis G, Pectasides D, Futreal A, Fountzilas G, Tsimberidou AM. Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget. 2020 Jan 07; 11(1):1-14. PMID: 32002119.
      Citations: 1     Fields:    
    30. Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 12 30; 12(1):145. PMID: 31888672.
      Citations: 8     Fields:    Translation:Humans
    31. Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers (Basel). 2019 Dec 10; 11(12). PMID: 31835495.
      Citations: 2     
    32. George GC, Mendoza TR, Iwuanyanwu EC, Manandhar M, Afshar SF, Piha-Paul SA, Tsimberidou A, Naing A, Cleeland CS, Hong DS. Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. Invest New Drugs. 2020 08; 38(4):1166-1174. PMID: 31761957.
      Citations:    Fields:    Translation:Humans
    33. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol. 2019; 3. PMID: 32923865.
      Citations: 2     
    34. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer. 2019 Oct; 136:158. PMID: 31445783.
      Citations:    Fields:    
    35. Said R, Tsimberidou AM. Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform. Cancer J. 2019 Jul/Aug; 25(4):282-286. PMID: 31335392.
      Citations: 6     Fields:    Translation:Humans
    36. Tsimberidou AM, Said R, Staudt LM, Conley BA, Takebe N. Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine. Cancer J. 2019 Jul/Aug; 25(4):296-299. PMID: 31335394.
      Citations: 1     Fields:    Translation:Humans
    37. Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758. PMID: 31011205.
      Citations: 90     Fields:    Translation:HumansCTClinical Trials
    38. Ou Y, Xu Y, Gore L, Harvey RD, Mita A, Papadopoulos KP, Wang Z, Cutler RE, Pinchasik DE, Tsimberidou AM. Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. Br J Clin Pharmacol. 2019 03; 85(3):530-539. PMID: 30428505.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    39. Fountzilas E, Palmer G, Vining D, Tsimberidou AM. Prolonged Partial Response to Bevacizumab and Valproic Acid in a Patient With Glioblastoma. JCO Precis Oncol. 2018; 2. PMID: 31544169.
      Citations:    
    40. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472. PMID: 30383888.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    41. Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA. Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer. 2018 10 19; 6(1):108. PMID: 30340549.
      Citations: 5     Fields:    Translation:Humans
    42. Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA. Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. J Clin Oncol. 2019 01 01; 37(1):72-80. PMID: 30339040.
      Citations: 6     Fields:    Translation:Humans
    43. Subbiah V, Sen S, Hess KR, Janku F, Hong DS, Khatua S, Karp DD, Munoz J, Falchook GS, Groisberg R, Tsimberidou AM, Sherman SI, Hwu P, Meric-Bernstam F. Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precis Oncol. 2018; 2. PMID: 32913986.
      Citations: 1     
    44. Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget. 2018 Sep 07; 9(70):33258-33270. PMID: 30279957.
      Citations: 1     Fields:    
    45. Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 2018 Sep 04; 9(69):33232-33243. PMID: 30237864.
      Citations: 6     Fields:    
    46. Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol. 2018 11; 82(5):877-885. PMID: 30182147.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    47. Ileana Dumbrava E, Smith V, Alfattal R, El-Naggar AK, Penas-Prado M, Tsimberidou AM. Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy. J Immunother. 2018 09; 41(7):336-339. PMID: 29787423.
      Citations: 2     Fields:    Translation:Humans
    48. Dumbrava EI, Alfattal R, Miller VA, Tsimberidou AM. Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient With Head and Neck Squamous Cell Carcinoma Harboring FGF Amplifications. JCO Precis Oncol. 2018; 2. PMID: 31123723.
      Citations: 2     
    49. Fountzilas E, Tsimberidou AM. Overview of precision oncology trials: challenges and opportunities. Expert Rev Clin Pharmacol. 2018 Aug; 11(8):797-804. PMID: 30044653.
      Citations: 10     Fields:    Translation:Humans
    50. Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS. Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget. 2018 Jun 22; 9(48):28842-28848. PMID: 29989021.
      Citations: 2     Fields:    
    51. Liu L, Toung JM, Jassowicz AF, Vijayaraghavan R, Kang H, Zhang R, Kruglyak KM, Huang HJ, Hinoue T, Shen H, Salathia NS, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Bibikova M, Granger G, Barnes B, Shen R, Gutekunst K, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder SL, Kopetz ES, Amaria RN, Meric-Bernstam F, Laird PW, Fan JB, Janku F. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann Oncol. 2018 06 01; 29(6):1445-1453. PMID: 29635542.
      Citations: 21     Fields:    Translation:HumansCells
    52. Xu Y, Müller P, Tsimberidou AM, Berry D. A nonparametric Bayesian basket trial design. Biom J. 2019 09; 61(5):1160-1174. PMID: 29808479.
      Citations:    Fields:    Translation:Humans
    53. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424. PMID: 29695765.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    54. Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601. PMID: 29654067.
      Citations: 9     Translation:HumansCells
    55. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141. PMID: 29748008.
      Citations: 10     Fields:    Translation:Humans
    56. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018 06 01; 36(16):1631-1641. PMID: 29504847.
      Citations: 192     Fields:    Translation:Humans
    57. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Arch Pathol Lab Med. 2018 10; 142(10):1242-1253. PMID: 29504834.
      Citations: 31     Fields:    Translation:Humans
    58. Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer. 2018 03 20; 118(6):763-769. PMID: 29462132.
      Citations: 5     Fields:    Translation:Humans
    59. Fountzilas E, Said R, Tsimberidou AM. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. Expert Opin Investig Drugs. 2018 02; 27(2):155-162. PMID: 29353505.
      Citations: 8     Fields:    Translation:Humans
    60. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN. Authors' Reply. J Mol Diagn. 2018 01; 20(1):125-126. PMID: 29249244.
      Citations:    Fields:    Translation:Humans
    61. Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Mol Cancer Ther. 2018 03; 17(3):671-676. PMID: 29237802.
      Citations: 8     Translation:HumansCTClinical Trials
    62. Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646. PMID: 29159766.
      Citations: 33     Fields:    Translation:Humans
    63. Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423. PMID: 29047029.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    64. Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188. PMID: 29051321.
      Citations: 47     Fields:    Translation:HumansCells
    65. Said R, Tsimberidou AM. Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. Expert Opin Biol Ther. 2017 11; 17(11):1463-1470. PMID: 28893099.
      Citations: 3     Fields:    Translation:Humans
    66. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017. PMID: 29082359.
      Citations: 43     
    67. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173. PMID: 29152071.
      Citations:    Fields:    
    68. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Aug 01; 23(15):4155-4162. PMID: 28729355.
      Citations: 1     Fields:    
    69. Subbiah IM, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S, Hong DS. Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience. 2017 May; 4(5-6):47-56. PMID: 28781987.
      Citations: 7     
    70. Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu S. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806. PMID: 28430579.
      Citations: 2     Fields:    Translation:Humans
    71. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8). PMID: 28422758.
      Citations: 10     Fields:    
    72. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35. PMID: 28428884.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    73. Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol. 2017 03 01; 28(3):642-650. PMID: 27993791.
      Citations: 22     Fields:    Translation:Humans
    74. Tsimberidou AM. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):176-181. PMID: 28410846.
      Citations: 6     Fields:    Translation:Humans
    75. Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. 2017 Jul 15; 23(14):3657-3666. PMID: 28096270.
      Citations: 21     Fields:    Translation:Humans
    76. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017 01; 19(1):4-23. PMID: 27993330.
      Citations: 320     Fields:    Translation:Humans
    77. Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444. PMID: 27882721.
      Citations: 9     Fields:    Translation:Humans
    78. Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah V. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology. 2017; 92(1):14-20. PMID: 27802448.
      Citations:    Fields:    Translation:Humans
    79. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients =65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. Int J Cancer. 2017 Jan 01; 140(1):208-215. PMID: 27599876.
      Citations: 3     Fields:    Translation:Humans
    80. Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448. PMID: 27748430.
      Citations: 6     Fields:    Translation:Humans
    81. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531. PMID: 27589687.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    82. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365. PMID: 27729313.
      Citations: 85     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    83. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396. PMID: 27649551.
      Citations: 109     Fields:    Translation:HumansCellsCTClinical Trials
    84. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 10; 15(10):2475-2485. PMID: 27466356.
      Citations: 30     Translation:HumansCells
    85. George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 2016 Nov 15; 122(21):3401-3409. PMID: 27412379.
      Citations: 8     Fields:    Translation:Humans
    86. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43. PMID: 27147567.
      Citations: 5     Fields:    Translation:Humans
    87. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404. PMID: 27207774.
      Citations: 31     Translation:HumansCells
    88. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res. 2016 07 01; 76(13):3690-701. PMID: 27197177.
      Citations: 86     Fields:    Translation:HumansCellsCTClinical Trials
    89. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38. PMID: 26933802.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    90. Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 05; 77(5):1097-102. PMID: 27085994.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    91. Tsimberidou AM. Health policy: Strategies to optimize expedited investigational new drug safety reports. Nat Rev Clin Oncol. 2016 Apr; 13(4):207-8. PMID: 26997460.
      Citations: 1     Fields:    Translation:Humans
    92. Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7. PMID: 27014780.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    93. Said R, Ye Y, Hong DS, Naing A, Falchook G, Fu S, Wheler JJ, Piha-Paul S, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 Mar; 77(3):575-81. PMID: 26825327.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    94. Tsimberidou AM, Kurzrock R. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol. 2015 Dec; 16(16):e579-80. PMID: 26678197.
      Citations: 18     Fields:    Translation:Humans
    95. Le Tourneau C, Kamal M, Tsimberidou AM, Bedard P, Pierron G, Callens C, Rouleau E, Vincent-Salomon A, Servant N, Alt M, Rouzier R, Paoletti X, Delattre O, Bièche I. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. J Natl Cancer Inst. 2016 Apr; 108(4). PMID: 26598514.
      Citations: 27     Fields:    Translation:HumansCells
    96. Fu S, Shi N, Wheler J, Naing A, Janku F, Piha-Paul S, Gong J, Hong D, Tsimberidou A, Zinner R, Subbiah V, Hou MM, Ramirez P, Ramondetta L, Lu K, Meric-Bernstam F. Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. Gynecol Oncol Res Pract. 2015; 2:10. PMID: 27231570.
      Citations: 4     
    97. Maiti A, Brown RE, Corn PG, Murthy R, Ganeshan DM, Tsimberidou AM, Subbiah V. Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates. Clin Genitourin Cancer. 2016 Apr; 14(2):e187-93. PMID: 26684814.
      Citations: 1     Fields:    Translation:HumansCells
    98. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015 Oct 16; 15:713. PMID: 26474549.
      Citations: 16     Fields:    Translation:Humans
    99. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94. PMID: 26330075.
      Citations: 12     Fields:    Translation:Humans
    100. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62. PMID: 26164085.
      Citations: 4     Fields:    Translation:Humans
    101. Tsimberidou AM. Targeted therapy in cancer. Cancer Chemother Pharmacol. 2015 Dec; 76(6):1113-32. PMID: 26391154.
      Citations: 34     Fields:    Translation:Humans
    102. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15; 6(27):24581. PMID: 26405159.
      Citations:    Fields:    
    103. Folsom AR, Yao L, Alonso A, Lutsey PL, Missov E, Lederle FA, Ballantyne CM, Tang W. Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015 Aug 18; 132(7):578-85. PMID: 32950605.
      Citations: 3     Fields:    
    104. Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs. 2015 Aug; 33(4):911-20. PMID: 25990659.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    105. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21. PMID: 25980577.
      Citations: 41     Fields:    Translation:Humans
    106. Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8. PMID: 25908602.
      Citations: 31     Fields:    Translation:Humans
    107. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7). PMID: 25863335.
      Citations: 82     Fields:    Translation:HumansAnimals
    108. Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015 Jun; 33(3):621-31. PMID: 25822109.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    109. Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clin Epigenetics. 2015; 7:29. PMID: 25806091.
      Citations: 8     Fields:    
    110. Wheler J, Yelensky R, Falchook G, Kim KB, Hwu P, Tsimberidou AM, Stephens PJ, Hong D, Cronin MT, Kurzrock R. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer. 2015 Feb 18; 15:61. PMID: 25886620.
      Citations: 11     Fields:    Translation:Humans
    111. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018. PMID: 25669829.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    112. Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Apr; 75(4):869-74. PMID: 25666183.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    113. Singh HM, Ungerechts G, Tsimberidou AM. Gene and cell therapy for pancreatic cancer. Expert Opin Biol Ther. 2015 Apr; 15(4):505-16. PMID: 25582170.
      Citations: 6     Fields:    Translation:HumansAnimals
    114. Said R, Tsimberidou AM. Left ventricular ejection fraction in advanced cancer patients: a valuable prognostic tool? Future Oncol. 2015; 11(14):1999-2002. PMID: 26198825.
      Citations:    Fields:    Translation:Humans
    115. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79. PMID: 25426553.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    116. Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33(1):215-24. PMID: 25363205.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    117. Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs. 2015 Feb; 33(1):177-86. PMID: 25323060.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    118. Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45. PMID: 25326232.
      Citations: 32     Fields:    Translation:Humans
    119. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46. PMID: 25313136.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    120. Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res. 2014 Dec 01; 20(23):5956-63. PMID: 25316815.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    121. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84. PMID: 25253784.
      Citations: 13     Fields:    Translation:HumansCells
    122. Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 2014; 1(8):540-9. PMID: 25594061.
      Citations: 9     
    123. Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah V. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. Oncoscience. 2014 Jul 27; 1(7):522-530. PMID: 25587555.
      Citations: 2     
    124. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36. PMID: 24987059.
      Citations: 82     Fields:    Translation:Humans
    125. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9. PMID: 25003695.
      Citations: 6     Fields:    Translation:Humans
    126. Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou A, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-?? and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec; 32(6):1204-12. PMID: 24919855.
      Citations: 22     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    127. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget. 2014 May 30; 5(10):3029-38. PMID: 24912489.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    128. Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget. 2014 May 30; 5(10):3012-22. PMID: 24931142.
      Citations: 43     Fields:    Translation:HumansCells
    129. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget. 2014 May 15; 5(9):2349-54. PMID: 24811890.
      Citations: 34     Fields:    Translation:Humans
    130. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55. PMID: 24778042.
      Citations: 5     Fields:    Translation:Humans
    131. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014 May; 15(6):656-66. PMID: 24746841.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    132. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul 15; 120(14):2164-73. PMID: 24752867.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    133. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. 2014 Apr 15; 5(7):1846-55. PMID: 24742900.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    134. Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One. 2014; 9(2):e89388. PMID: 24586741.
      Citations: 25     Fields:    Translation:Humans
    135. Said R, Tsimberidou AM. Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Expert Opin Drug Metab Toxicol. 2014 Mar; 10(3):483-94. PMID: 24512004.
      Citations: 14     Fields:    Translation:Humans
    136. Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G. A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):395-400.e1. PMID: 24637132.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    137. Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb; 12(2):194-203. PMID: 24586081.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    138. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014 Mar; 73(3):495-501. PMID: 24435060.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    139. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87. PMID: 24440717.
      Citations: 107     Fields:    Translation:HumansCTClinical Trials
    140. Said R, Banchs J, Wheler J, Hess KR, Falchook G, Fu S, Naing A, Hong D, Piha-Paul S, Ye Y, Yeh E, Wolff RA, Tsimberidou AM. The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol. 2014 Jan; 25(1):276-82. PMID: 24356639.
      Citations: 3     Fields:    Translation:Humans
    141. Rolfo C, Fanale D, Hong DS, Tsimberidou AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V, Cicero G, Russo A, Giovannetti E. Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. Curr Pharm Biotechnol. 2014; 15(5):475-85. PMID: 24846062.
      Citations: 27     Fields:    Translation:HumansAnimals
    142. Tsimberidou AM, Eggermont AM, Schilsky RL. Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014; 61-9. PMID: 24857061.
      Citations: 16     Fields:    Translation:Humans
    143. Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience. 2014; 1(1):5-13. PMID: 25593979.
      Citations: 17     
    144. Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs. 2014 Jun; 32(3):465-72. PMID: 24306314.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    145. Fu S, McQuinn L, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul SA, Tu D, Howard A, Tsimberidou A, Zinner R, Hong DS, Kurzrock R. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist. 2013; 18(12):1315-20. PMID: 24153239.
      Citations: 11     Fields:    Translation:Humans
    146. Garcia SS, Atkins JT, Falchook GS, Tsimberidou AM, Hong DS, Trivedi MV, Kurzrock R. Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1265-71. PMID: 24101145.
      Citations: 2     Fields:    Translation:Humans
    147. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63. PMID: 24092809.
      Citations: 16     Fields:    Translation:HumansCells
    148. Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology. 2013 Oct; 60(127):1611-23. PMID: 24634931.
      Citations: 6     Fields:    Translation:Humans
    149. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Janku F, Zinner R, Laday S, Kies M, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Invest New Drugs. 2013 Dec; 31(6):1505-13. PMID: 23982248.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    150. Xu-Monette ZY, Møller MB, Tzankov A, Montes-Moreno S, Hu W, Manyam GC, Kristensen L, Fan L, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Wu L, Zhao X, Bueso-Ramos CE, Wang SA, Go RS, Li Y, Winter JN, Piris MA, Medeiros LJ, Young KH. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 Oct 10; 122(15):2630-40. PMID: 23847722; PMCID: PMC3952598.
      Citations:    
    151. Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther. 2013 Oct; 12(10):2167-75. PMID: 23963360.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    152. Veasey-Rodrigues H, Parsons HA, Janku F, Naing A, Wheler JJ, Tsimberidou AM, Kurzrock R. A pilot study of temsirolimus and body composition. J Cachexia Sarcopenia Muscle. 2013 Dec; 4(4):259-65. PMID: 23893509.
      Citations: 8     Fields:    
    153. Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 01; 19(17):4824-31. PMID: 23873691.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    154. Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, Fu S, Falchoock G, Tsimberidou AM, Piha-Paul S, Chisholm G, Kurzrock R. Body composition and survival in the early clinical trials setting. Eur J Cancer. 2013 Oct; 49(15):3068-75. PMID: 23867127.
      Citations: 12     Fields:    Translation:Humans
    155. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):568-74. PMID: 23810245.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    156. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. 2014 Apr; 32(2):279-86. PMID: 23756764.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    157. Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget. 2013 Jun; 4(6):890-8. PMID: 23765114.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    158. Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget. 2013 May; 4(5):772-84. PMID: 23800712.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    159. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013 May; 4(5):705-14. PMID: 23670029.
      Citations: 57     Fields:    Translation:Humans
    160. Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol. 2013 Aug; 24(8):2158-65. PMID: 23576709.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    161. Féliz LR, Tsimberidou AM. Anti-vascular endothelial growth factor therapy in the era of personalized medicine. Cancer Chemother Pharmacol. 2013 Jul; 72(1):1-12. PMID: 23463481.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    162. Tsimberidou AM, Ye Y, Wheler J, Naing A, Hong D, Nwosu U, Hess KR, Wolff RA. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol. 2013 Apr; 71(4):955-63. PMID: 23377373.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    163. Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM, Kurzrock R. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol. 2013 Mar 20; 31(9):e137-40. PMID: 23358976.
      Citations: 14     Fields:    Translation:Humans
    164. Shim S, Stemke-Hale K, Tsimberidou AM, Noshari J, Anderson TE, Gascoyne PR. Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis. Biomicrofluidics. 2013; 7(1):11807. PMID: 24403989.
      Citations: 49     
    165. Tsimberidou AM, Ringborg U, Schilsky RL. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book. 2013; 118-25. PMID: 23714475.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    166. Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget. 2013 Jan; 4(1):118-27. PMID: 23435217.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    167. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65. PMID: 23391555.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    168. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75. PMID: 23248156.
      Citations: 45     Fields:    Translation:Humans
    169. Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol. 2013 Feb; 71(2):389-97. PMID: 23143207.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    170. Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol. 2013 Mar; 24(3):838-42. PMID: 23139256.
      Citations: 10     Fields:    Translation:Humans
    171. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84. PMID: 23066039.
      Citations: 126     Fields:    Translation:HumansCells
    172. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83. PMID: 22966018.
      Citations: 211     Fields:    Translation:Humans
    173. Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R. Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol. 2012 Aug 10; 30(23):2891-6. PMID: 22778314.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    174. Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol. 2012 Nov; 23(11):2960-2963. PMID: 22745218.
      Citations: 17     Fields:    Translation:Humans
    175. Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology. 2012 Jun; 59(116):960-4. PMID: 22580643.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    176. Segler A, Tsimberidou AM. Lenalidomide in solid tumors. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1393-406. PMID: 22584909.
      Citations: 10     Fields:    Translation:HumansCells
    177. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer. 2012 Dec; 11(4):297-303. PMID: 22537607.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    178. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res. 2012 May 15; 18(10):2922-9. PMID: 22452943.
      Citations: 38     Fields:    Translation:Humans
    179. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol. 2012 Aug; 23(8):1963-1967. PMID: 22377564.
      Citations: 8     Fields:    Translation:Humans
    180. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82. PMID: 22271473.
      Citations: 205     Fields:    Translation:Humans
    181. Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer. 2012; 64(2):206-17. PMID: 22229660.
      Citations: 6     Fields:    Translation:Humans
    182. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One. 2011; 6(10):e25806. PMID: 22039425.
      Citations: 34     Fields:    Translation:Humans
    183. El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R. Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist. 2011; 16(9):1292-8. PMID: 21859821.
      Citations: 19     Fields:    Translation:Humans
    184. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012 Mar 01; 118(5):1422-8. PMID: 21823111.
      Citations: 31     Fields:    Translation:Humans
    185. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769. PMID: 21829508.
      Citations: 91     Fields:    Translation:Humans
    186. Subbiah IM, Lenihan DJ, Tsimberidou AM. Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist. 2011; 16(8):1120-30. PMID: 21742963.
      Citations: 24     Fields:    Translation:Humans
    187. Tsimberidou AM, Lewis N, Reid T, Burris H, Urban P, Tan EY, Anand S, Uehara C, Kurzrock R. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1507-16. PMID: 21499896.
      Citations: 2     Fields:    Translation:Humans
    188. Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R. Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clin Cancer Res. 2011 Jun 15; 17(12):4110-8. PMID: 21415223.
      Citations: 7     Fields:    Translation:Humans
    189. Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist. 2011; 16(3):327-35. PMID: 21339262.
      Citations: 4     Fields:    Translation:Humans
    190. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005. PMID: 21289252.
      Citations: 36     Fields:    Translation:HumansCellsCTClinical Trials
    191. Vaklavas C, Chatzizisis YS, Tsimberidou AM. Common cardiovascular medications in cancer therapeutics. Pharmacol Ther. 2011 May; 130(2):177-90. PMID: 21277894.
      Citations: 20     Fields:    Translation:Humans
    192. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011 Mar; 10(3):558-65. PMID: 21216929.
      Citations: 164     Fields:    Translation:Humans
    193. Tsimberidou AM, Takimoto CH, Moulder S, Uehara C, Mita M, Mita A, Urban P, Tan E, Wang Y, Vining D, Kurzrock R. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther. 2011 Jan; 10(1):209-17. PMID: 21220503.
      Citations: 2     Translation:HumansCTClinical Trials
    194. Tsimberidou AM, Minotti G, Cardinale D. Managing cardiac risk factors in oncology clinical trials. Tex Heart Inst J. 2011; 38(3):266-7. PMID: 21720468.
      Citations: 2     Fields:    Translation:Humans
    195. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther. 2010 Dec; 9(12):3410-9. PMID: 21159616.
      Citations: 11     Translation:HumansCTClinical Trials
    196. Tsimberidou AM, Chandhasin C, Kurzrock R. Farnesyltransferase inhibitors: where are we now? Expert Opin Investig Drugs. 2010 Dec; 19(12):1569-80. PMID: 21083522.
      Citations: 19     Fields:    Translation:HumansAnimals
    197. Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2011 Jul; 68(1):247-53. PMID: 20941597.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    198. Vaklavas C, Sotelo-Rafiq EP, Lovy J, Escobar MA, Tsimberidou AM. Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. Virol J. 2010 Sep 28; 7:256. PMID: 20920200.
      Citations: 4     Fields:    Translation:HumansCells
    199. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010 Sep 01; 116(17):4086-94. PMID: 20564148.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    200. Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer. 2011 Jan 01; 117(1):77-85. PMID: 20737567.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    201. Tsimberidou AM, Keating MJ. Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. Leuk Lymphoma. 2010 Jul; 51(7):1188-99. PMID: 20545582.
      Citations: 5     Fields:    Translation:Humans
    202. Tsimberidou AM. Ofatumumab in the treatment of chronic lymphocytic leukemia. Drugs Today (Barc). 2010 Jul; 46(7):451-61. PMID: 20683500.
      Citations: 1     Fields:    Translation:Humans
    203. Bustinza-Linares E, Kurzrock R, Tsimberidou AM. Salirasib in the treatment of pancreatic cancer. Future Oncol. 2010 Jun; 6(6):885-91. PMID: 20528225.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    204. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1087-93. PMID: 20204368.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    205. Tarrand JJ, Keating MJ, Tsimberidou AM, O'Brien S, LaSala RP, Han XY, Bueso-Ramos CE. Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. Cancer. 2010 Feb 15; 116(4):880-7. PMID: 20052729.
      Citations: 14     Fields:    Translation:HumansCells
    206. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist. 2010; 15(2):130-41. PMID: 20139170.
      Citations: 30     Fields:    Translation:HumansAnimals
    207. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clin Breast Cancer. 2010 Feb; 10(1):46-51. PMID: 20133258.
      Citations: 5     Fields:    Translation:Humans
    208. Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol. 2010 Jan; 65(2):235-41. PMID: 19484470.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    209. Aguilera DG, Vaklavas C, Tsimberidou AM, Wen S, Medeiros LJ, Corey SJ. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience. J Pediatr Hematol Oncol. 2009 Nov; 31(11):803-11. PMID: 19801947.
      Citations: 13     Fields:    Translation:Humans
    210. Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. J Clin Oncol. 2009 Dec 20; 27(36):6243-50. PMID: 19826112.
      Citations: 25     Fields:    Translation:Humans
    211. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab. 2009 Nov; 94(11):4423-32. PMID: 19820016.
      Citations: 17     Fields:    Translation:Humans
    212. Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res. 2009 Jul 15; 15(14):4769-76. PMID: 19584162.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    213. Vemulapalli S, Chintala L, Tsimberidou AM, Dhillon N, Lei X, Hong D, Kurzrock R. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. Am J Hematol. 2009 Jul; 84(7):408-13. PMID: 19437507.
      Citations: 6     Fields:    Translation:Humans
    214. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2009 Jul 01; 115(13):2824-36. PMID: 19402170.
      Citations: 21     Fields:    Translation:Humans
    215. Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag. 2009 Apr; 5(2):281-9. PMID: 19536317.
      Citations: 22     
    216. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer. 2009 Mar 01; 115(5):1091-9. PMID: 19165805.
      Citations: 31     Fields:    Translation:Humans
    217. Tsimberidou AM, Tam C, Abruzzo LV, O'Brien S, Wierda WG, Lerner S, Kantarjian HM, Keating MJ. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer. 2009 Jan 15; 115(2):373-80. PMID: 19117034.
      Citations: 36     Fields:    Translation:HumansCells
    218. Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009 Feb 20; 27(6):904-10. PMID: 19114699.
      Citations: 62     Fields:    Translation:Humans
    219. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer. 2008 Oct 01; 113(7):1605-13. PMID: 18683214.
      Citations: 34     Fields:    Translation:Humans
    220. Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros LJ, Estey E. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer. 2008 Sep 15; 113(6):1370-8. PMID: 18623376.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    221. Tsimberidou AM, Estey E. Relevance of clinical trials in acute myeloid leukaemia. Hematol Oncol. 2008 Sep; 26(3):182-3. PMID: 18381703.
      Citations: 3     Fields:    Translation:Humans
    222. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res. 2008 Feb 01; 14(3):721-30. PMID: 18245532.
      Citations: 20     Fields:    Translation:Humans
    223. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203. PMID: 18182662.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    224. Tsimberidou AM, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ, Kantarjian HM, Medeiros LJ, Keating MJ. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2007 Oct 10; 25(29):4648-56. PMID: 17925562.
      Citations: 20     Fields:    Translation:Humans
    225. Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma. 2007 Oct; 48(10):1931-9. PMID: 17917961.
      Citations: 26     Fields:    Translation:Humans
    226. Tsimberidou AM, Keating MJ, Wierda WG. Richter's transformation in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2007 Oct; 2(4):265-71. PMID: 20425379.
      Citations: 7     Fields:    Translation:Humans
    227. Ahmed B, Estey E, Manning J, David C, Keating MJ, Kantarjian H, Tsimberidou AM. Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature. Haematologica. 2006 Dec; 91(12 Suppl):ECR55. PMID: 17194661.
      Citations: 3     Fields:    Translation:Humans
    228. Tsimberidou AM, Kantarjian H, Keating MJ, Estey E. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Leuk Lymphoma. 2006 Nov; 47(11):2282-8. PMID: 17107899.
      Citations: 4     Fields:    Translation:Humans
    229. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer. 2006 Sep 15; 107(6):1294-302. PMID: 16902984.
      Citations: 24     Fields:    Translation:Humans
    230. Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006 Aug; 47(8):1267-73. PMID: 16883004.
      Citations: 46     Fields:    Translation:Humans
    231. Tsimberidou AM, Estey E. Induction mortality risk in adult acute myeloid leukemia. Leuk Lymphoma. 2006 Jul; 47(7):1199-200. PMID: 16923545.
      Citations: 1     Fields:    Translation:HumansCells
    232. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006 Jul 01; 107(1):125-35. PMID: 16700034.
      Citations: 18     Fields:    Translation:Humans
    233. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma. 2006 Jun; 47(6):1062-8. PMID: 16840198.
      Citations: 17     Fields:    Translation:Humans
    234. Tsimberidou AM, Estey E, Kantarjian H, Keating MJ, Pierce S, Garcia-Manero G. Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. Leukemia. 2006 Aug; 20(8):1452-3. PMID: 16728980.
      Citations: 2     Fields:    Translation:HumansCells
    235. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 May 20; 24(15):2343-51. PMID: 16710033.
      Citations: 57     Fields:    Translation:Humans
    236. Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma. 2006 May; 47(5):827-36. PMID: 16753866.
      Citations: 15     Fields:    Translation:HumansCells
    237. Garcia MG, Deavers MT, Knoblock RJ, Chen W, Tsimberidou AM, Manning JT, Medeiros LJ. Myeloid sarcoma involving the gynecologic tract: a report of 11 cases and review of the literature. Am J Clin Pathol. 2006 May; 125(5):783-90. PMID: 16707383.
      Citations: 14     Fields:    Translation:Humans
    238. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006 Apr 01; 24(10):1582-9. PMID: 16575009.
      Citations: 41     Fields:    Translation:Humans
    239. Tsimberidou AM, Keating MJ. Richter's transformation in chronic lymphocytic leukemia. Semin Oncol. 2006 Apr; 33(2):250-6. PMID: 16616072.
      Citations: 16     Fields:    Translation:Humans
    240. Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol. 2006 Feb; 132(4):398-409. PMID: 16412015.
      Citations: 16     Fields:    Translation:HumansCells
    241. Beddar AS. Stability of a mobile electron linear accelerator system for intraoperative radiation therapy. Med Phys. 2005 Oct; 32(10):3128-31. PMID: 25902899.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    242. Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, Ayala A, Smith TL, Cabanillas F, McLaughlin P. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer. 2005 Jul 15; 104(2):345-53. PMID: 15948158.
      Citations: 4     Fields:    Translation:Humans
    243. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005 Jun; 29(6):649-52. PMID: 15863204.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    244. Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, Tirado-Gomez M, Lopez-Berestein G, Kantarjian H. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood. 2005 Feb 01; 105(3):1366-7. PMID: 15659618.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    245. Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2005 Jan 15; 103(2):216-28. PMID: 15578683.
      Citations: 57     Fields:    Translation:Humans
    246. Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol. 2005 Jan; 16(1):139-45. PMID: 15598951.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    247. Tsimberidou AM, Keating MJ. Hyperuricemic syndromes in cancer patients. Contrib Nephrol. 2005; 147:47-60. PMID: 15604605.
      Citations: 6     Fields:    Translation:Humans
    248. Tsimberidou AM, Estey E, Whitman GJ, Dryden MJ, Ratnam S, Pierce S, Faderl S, Giles F, Kantarjian HM, Garcia-Manero G. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res. 2004 Sep; 28(9):991-4. PMID: 15234578.
      Citations: 7     Fields:    Translation:Humans
    249. Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol. 2004 Aug; 51(2):200-4. PMID: 15280837.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    250. Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer. 2004 Jun 15; 100(12):2583-91. PMID: 15197800.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    251. Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res. 2004 Jun; 28(6):657-60. PMID: 15120945.
      Citations: 4     Fields:    Translation:Humans
    252. Tsimberidou AM, Murray JL, O'Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer. 2004 May 15; 100(10):2195-200. PMID: 15139064.
      Citations: 9     Fields:    Translation:Humans
    253. Tsimberidou AM, Giles F, Romaguera J, Duvic M, Kurzrock R. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer. 2004 Feb 01; 100(3):574-80. PMID: 14745875.
      Citations: 5     Fields:    Translation:Humans
    254. Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer. 2004 Jan 15; 100(2):342-9. PMID: 14716770.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    255. Yazji S, Giles FJ, Tsimberidou AM, Estey EH, Kantarjian HM, O'Brien SA, Kurzrock R. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia. 2003 Nov; 17(11):2101-6. PMID: 12931212.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    256. Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O'Brien SM. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma. 2003 Oct; 44(10):1719-25. PMID: 14692524.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    257. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2003 Oct; 27(10):893-7. PMID: 12860008.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    258. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res. 2003 Oct; 27(10):887-91. PMID: 12860007.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    259. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 2003 Dec; 52(6):449-52. PMID: 13680159.
      Citations: 4     Fields:    Translation:Humans
    260. Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia. 2003 Jun; 17(6):1100-3. PMID: 12764375.
      Citations: 69     Fields:    Translation:HumansCells
    261. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol. 2003 Sep; 52(3):229-34. PMID: 12783207.
      Citations: 1     Fields:    Translation:Humans
    262. Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res. 2003 May; 27(5):375-80. PMID: 12620287.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    263. Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H, Giles FJ. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leuk Res. 2003 Apr; 27(4):301-4. PMID: 12531220.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    264. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 01; 97(7):1711-20. PMID: 12655528.
      Citations: 23     Fields:    Translation:Humans
    265. Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, Skandali A, Sakellari I, Yataganas X. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer. 2003 Apr 01; 97(7):1721-31. PMID: 12655529.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    266. Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003 Mar 15; 97(6):1481-7. PMID: 12627513.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    267. Tsimberidou AM, Medina J, Earl M, Sierra M, Shriki JE, Bueso-Ramos C, Giralt S, Beran M, Giles FJ, Garcia-Manero G. Metastatic gastric adenocarcinoma following allogeneic stem cell transplantation in a patient with acute myelogenous leukemia. Bone Marrow Transplant. 2003 Mar; 31(5):413-4. PMID: 12634736.
      Citations:    Fields:    Translation:Humans
    268. Tsimberidou AM, Giles FJ. Essential thrombocythemia (ET): moving from palliation to cure. Hematology. 2002 Dec; 7(6):315-23. PMID: 12475736.
      Citations:    Fields:    Translation:Humans
    269. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):87-90. PMID: 12497211.
      Citations: 8     Fields:    Translation:Humans
    270. Cortes J, Tsimberidou AM, Alvarez R, Thomas D, Beran M, Kantarjian H, Estey E, Giles FJ. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol. 2002 Dec; 50(6):497-500. PMID: 12451477.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    271. Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, Romaguera J, Hess M, Smith TL, Yang Y, Ayala A, Preti A, Lee MS, Cabanillas F. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood. 2002 Dec 15; 100(13):4351-7. PMID: 12393618.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    272. Tsimberidou AM, Alvarado Y, Giles FJ. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther. 2002 Aug; 2(4):437-48. PMID: 12647987.
      Citations: 14     Fields:    Translation:Humans
    273. Tsimberidou AM, Jiang Y, Ford RJ, Lichtiger B, Medeiros LJ, McLaughlin P, Cabanillas F, Sarris AH. Quantitative real-time polymerase chain reaction for detection of circulating cells with t(14;18) in volunteer blood donors and patients with follicular lymphoma. Leuk Lymphoma. 2002 Aug; 43(8):1589-98. PMID: 12400601.
      Citations: 2     Fields:    Translation:HumansCells
    274. Tsimberidou AM, Thomas D, O'Brien S, Andreeff M, Kurzrock R, Keating M, Albitar M, Kantarjian H, Giles F. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol. 2002 Sep; 50(3):237-42. PMID: 12203106.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    275. Tsimberidou AM, Giles FJ. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther. 2002 Jun; 2(3):277-86. PMID: 12113051.
      Citations: 6     Fields:    Translation:Humans
    276. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002 Apr; 43(4):767-72. PMID: 12153163.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    277. Sarris AH, Jiang Y, Tsimberidou AM, Thomaides A, Rassidakis GZ, Ford RJ, Medeiros LJ, Cabanillas F, McLaughlin P. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Semin Oncol. 2002 Feb; 29(1 Suppl 2):48-55. PMID: 11842389.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    278. Tsimberidou AM, Paterakis G, Androutsos G, Anagnostopoulos N, Galanopoulos A, Kalmantis T, Meletis J, Rombos Y, Sagriotis A, Symeonidis A, Tiniakou M, Zoumbos N, Yataganas X. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk Res. 2002 Feb; 26(2):143-54. PMID: 11755464.
      Citations: 6     Fields:    Translation:HumansCells
    279. Sarris AH, Jiang Y, Tsimberidou AM, Thomaides A, Rassidakis GZ, Ford RJ, Medeiros LJ, Cabanillas F, McLaughlin P. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Semin Oncol. 2002 Feb; 29(1S2):48-55. PMID: 28140092.
      Citations:    Fields:    
    280. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F. Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma. 2001 May; 41(5-6):535-44. PMID: 11378571.
      Citations: 1     Fields:    Translation:Humans
    281. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000 Jan; 11(1):69-72. PMID: 10690390.
      Citations: 26     Fields:    Translation:HumansAnimalsCTClinical Trials
    282. Meletis J, Samarkos M, Mesogitis S, Meletis C, Mougiou A, Terpos E, Tsimberidou A, Andreopoulos A, Konstantopoulos K, Loukopoulos D. Severe aplastic anaemia relapsing during a pregnancy; spontaneous remission following termination. Haematologia (Budap). 1998; 29(2):147-51. PMID: 9728807.
      Citations: 1     Fields:    Translation:Humans
    283. Meletis J, Michali E, Samarkos M, Konstantopoulos K, Meletis C, Terpos E, Tsimberidou A, Chandrinou E, Viniou N, Rombos Y, Pangalis GA, Yataganas X, Loukopoulos D. Detection of "PNH red cell" populations in hematological disorders using the Sephacryl Gel Test micro typing system. Leuk Lymphoma. 1997 Dec; 28(1-2):177-82. PMID: 9498717.
      Citations: 3     Fields:    Translation:HumansCells
    284. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemotherapy and Pharmacology. 1-5.
    285. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults. Oncoscience. 1:522-530.
    286. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma. Oncotarget. 6:28453-28462.
    287. Treatment algorithms based on tumor molecular profiling. Journal of the National Cancer Institute. 108.
    288. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 1:540-549.
    289. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 7:23227-23238.
    290. TP53 alterations correlate with response to VEGF/VEGFR inhibitors. Molecular Cancer Therapeutics. 15:2475-2485.
    291. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 1-6.
    292. BRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Molecular Cancer Therapeutics. 15:1397-1404.
    293. International Journal of Cancer. 140:208-215.
    294. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). Journal of Clinical Endocrinology and Metabolism. 96:2286.
    295. Phase i study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics. 7:1-11.
    296. Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis. Biomicrofluidics. 7.
    297. Cancer therapy directed by comprehensive genomic profiling. Cancer Research. 76:3690-3701.
    298. Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma. Clinical Genitourinary Cancer. 14:e187-e193.
    299. Treatment of older patients with acute myeloid leukemia. Aging Health. 3:663-673.
    300. Chronic lymphocytic leukemia/small lymphocytic lymphoma. 211-223.
    301. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 6:12809-12821.
    302. Richter's syndrome. American Journal of Oncology Review. 5:662-665.
    303. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Investigational New Drugs.
    304. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, (997-1005)). Journal of Clinical Endocrinology and Metabolism. 97:1399.
    305. Survival of patients with metastatic leiomyosarcoma. Cancer Medicine. 5:3437-3444.
    306. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. Journal of Molecular Diagnostics. 19:4-23.
    307. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. American Journal of Hematology/ Oncology. 8.
    308. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discovery. 6:1352-1365.
    309. The significance of anemia in elderly patients with cancer. Oncology. 21.
    310. Treating newly diagnosed CLL. Clinical Advances in Hematology and Oncology. 8.
    311. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer. BMC Cancer. 15.
    312. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer. Oncotarget. 7:35132-35143.
    313. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 7:67521-67531.
    314. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 122:3401-3409.
    315. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports. 6.
    316. Challenges in initiating and conducting personalized cancer therapy trials. Annals of Oncology. 26:1791-1798.
    317. Erratum to "Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies" [Oncotarget., 6 (2015) 12809-12821]. Oncotarget. 6:24581.
    318. MET nucleotide variations and amplification in advanced ovarian cancer. Oncoscience. 1:5-13.
    319. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Investigational New Drugs. 33:621-631.
    320. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 6:26886-26894.
    321. Erratum. Cancer. 115:1588.
    322. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology (Switzerland).
    TSIMBERIDOU's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (700)
    Explore
    _
    Co-Authors (179)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _